In his op-ed, “Trump Admin Takes Pro-Patient Approach to Drug Prices,” Public Policy Solution’s President Joe Grogan argues that initiatives like the TrumpRx platform, which offers discounted cash prices on dozens of high-demand medications, are designed to foster competition and allow consumers to bypass opaque middlemen such as pharmacy benefit managers (PBMs). The broader strategy also includes transparency rules and new oversight of PBMs to expose hidden pricing practices and give patients clearer information about their healthcare costs. Ultimately, Grogan contends that empowering consumers, not expanding government control, offers a more sustainable path to affordable medicines
In his op-ed, Joe writes:
” For the uninsured, those navigating health savings accounts or enrollees facing coverage gaps in their insurance plans, TrumpRx represents a lifeline. It empowers patients to take the reins of their drug expenditures, bypassing the opaque machinations of intermediaries. In some cases, prices could rival those negotiated by Medicare itself—and, in rare but telling instances, undercut what insured patients might pay through their own plans”
Read the full op-ed at Newsweek.